{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:45:50Z","timestamp":1790275550081,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.hoc.2014.08.015","type":"journal-article","created":{"date-parts":[[2014,9,21]],"date-time":"2014-09-21T22:31:54Z","timestamp":1411338714000},"page":"1073-1095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"28","author":[{"given":"Vijaya Raj","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib2","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib3","first-page":"616","article-title":"Comorbidity, lactate dehydrogenase (LDH), and chemosensitivity are independent predictors of mortality after autologous hematopoietic cell transplantation (HCT) for patients (pts) with lymphoma","volume":"110","author":"Sorror","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2007-01-041871","article-title":"How I treat patients with diffuse large B-cell lymphoma","volume":"110","author":"Armitage","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2014.08.015_bib6","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib7","article-title":"High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults","author":"Greb","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.hoc.2014.08.015_bib8","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2014.08.015_bib9","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol\u2013a groupe d'Etude des lymphomes de l'Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2014.08.015_bib10","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.hoc.2014.08.015_bib11","first-page":"106","volume":"22","author":"Vitolo","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2014.08.015_bib12","first-page":"685","article-title":"No benefit of first-line rituximab (R) - high-dose therapy (R-HDT) over R-CHOP14 for young adults with diffuse large B-cell lymphoma. Preliminary results of the GOELAMS 075 prospective multicentre randomized trial","volume":"116","author":"Milpied","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"10.1016\/j.hoc.2014.08.015_bib13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2014.08.015_bib14","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJMe1309182","article-title":"Myeloablation for lymphoma\u2013question answered?","volume":"369","author":"Milpied","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2014.08.015_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2014.08.015_bib17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry","volume":"19","author":"Vose","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2014.08.015_bib19","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib20","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib21","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","article-title":"Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas","volume":"23","author":"Khouri","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2003.09.015","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission","volume":"10","author":"Vose","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"10.1016\/j.hoc.2014.08.015_bib23","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2014.08.015_bib24","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"31","key":"10.1016\/j.hoc.2014.08.015_bib25","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib26","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2005-04-1603","article-title":"Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL","volume":"106","author":"Moskowitz","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.1017","article-title":"Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation","volume":"30","author":"Gu","year":"2012","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib28","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":"Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"27","author":"Winter","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib29","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A\u00a0phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2014.08.015_bib30","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A\u00a0phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2011.03.007","article-title":"(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study","volume":"11","author":"Decaudin","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbmt.2012.08.013","article-title":"Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma","volume":"19","author":"Vose","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3324\/haematol.2013.093450","article-title":"Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus beam in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial","volume":"99","author":"Briones","year":"2014","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.hoc.2014.08.015_bib34","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib35","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib37","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/annonc\/mdq235","article-title":"High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma","volume":"21","author":"Glass","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bmt.1705414","article-title":"A\u00a0phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma","volume":"38","author":"Coso","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-006-0210-5","article-title":"Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma","volume":"86","author":"Sieniawski","year":"2007","journal-title":"Ann Hematol"},{"issue":"36","key":"10.1016\/j.hoc.2014.08.015_bib40","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.08.015_bib41","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.08.015_bib42","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.22911","article-title":"The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation","volume":"110","author":"Filmont","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy","volume":"150","author":"Dickinson","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/bmt.2010.130","article-title":"Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients","volume":"46","author":"Roland","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib45","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.23524","article-title":"Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era","volume":"88","author":"Nagle","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A\u00a0comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib47","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2014.08.015_bib48","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib49","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2014.08.015_bib50","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2014.08.015_bib51","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib52","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2014.08.015_bib53","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib54","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib55","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.08.015_bib56","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib57","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib59","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.hoc.2014.08.015_bib60","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2014.08.015_bib61","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","article-title":"Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission","volume":"13","author":"Brown","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.hoc.2014.08.015_bib62","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/annonc\/mdn044","article-title":"Immunochemotherapy with in\u00a0vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma","volume":"19","author":"Arcaini","year":"2008","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib63","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.08.015_bib64","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdp484","article-title":"Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma","volume":"21","author":"Kasamon","year":"2010","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2014.08.015_bib65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib66","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/annonc\/mds202","volume":"23","author":"Morschhauser","year":"2012","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2014.08.015_bib67","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib68","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","article-title":"Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes","volume":"22","author":"Corradini","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib69","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2014.08.015_bib70","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib71","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","article-title":"Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma","volume":"141","author":"Ingram","year":"2008","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.hoc.2014.08.015_bib73","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2014.08.015_bib74","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.23615","article-title":"Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management","volume":"88","author":"Vose","year":"2013","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2014.08.015_bib75","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"36","key":"10.1016\/j.hoc.2014.08.015_bib77","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib78","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2014.08.015_bib79","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","article-title":"Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database","volume":"119","author":"LaCasce","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2014.08.015_bib80","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation","volume":"29","author":"Budde","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.08.015_bib81","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1083-8791(00)70030-9","article-title":"Autologous hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"6","author":"Vose","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2014.08.015_bib82","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2014.08.015_bib83","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"issue":"1 Suppl 2","key":"10.1016\/j.hoc.2014.08.015_bib85","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/sonc.2002.30143","article-title":"Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma","volume":"29","author":"Mangel","year":"2002","journal-title":"Semin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2014.08.015_bib86","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","article-title":"Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma","volume":"27","author":"Andersen","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib87","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/bmt.2011.218","article-title":"Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance","volume":"47","author":"Ahmadi","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib88","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2013.332","article-title":"Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma","volume":"28","author":"Dietrich","year":"2014","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2014.08.015_bib89","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2014.08.015_bib90","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bbmt.2013.07.005","article-title":"Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation","volume":"19","author":"Cassaday","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hoc.2014.08.015_bib91","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2014.08.015_bib92","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.08.015_bib93","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib94","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1080\/10428190802419640","article-title":"Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study","volume":"49","author":"Hsi","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib95","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.hoc.2014.08.015_bib96","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.08.015_bib97","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib98","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.23536","article-title":"The aggressive peripheral T-cell lymphomas: 2013","volume":"88","author":"Armitage","year":"2013","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.hoc.2014.08.015_bib99","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2014.08.015_bib100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2014.08.015_bib101","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2014.08.015_bib102","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","article-title":"High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"20","author":"Nickelsen","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.08.015_bib103","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00277-013-1685-5","article-title":"Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial","volume":"92","author":"Ahn","year":"2013","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2014.08.015_bib104","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.015_bib105","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.bbmt.2011.02.008","article-title":"High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors","volume":"17","author":"Nademanee","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib106","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2014.08.015_bib107","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.11173","article-title":"The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing\/refractory peripheral T-cell lymphoma","volume":"92","author":"Rodriguez","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2014.08.015_bib108","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib109","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","article-title":"Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen","volume":"40","author":"Smith","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.hoc.2014.08.015_bib110","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2014.08.015_bib111","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2014.08.015_bib112","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","article-title":"Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas","volume":"150","author":"Shustov","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2014.08.015_bib113","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2010.08549.x","article-title":"The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls","volume":"152","author":"Hill","year":"2011","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2014.08.015_bib114","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4161\/cbt.26342","article-title":"Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients","volume":"14","author":"Akhtari","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"10.1016\/j.hoc.2014.08.015_bib115","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2010-10-263095","article-title":"How I treat late effects in adults after allogeneic stem cell transplantation","volume":"117","author":"Savani","year":"2011","journal-title":"Blood"},{"issue":"1 Suppl","key":"10.1016\/j.hoc.2014.08.015_bib116","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbmt.2008.10.009","article-title":"Late effects after autologous hematopoietic cell transplantation","volume":"15","author":"Burns","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:01:35Z","timestamp":1760184095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858814001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0889858814001154"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.015","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}